• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

MSD - Articles and news items

eu hepatitis c european market

MSD’s Hepatitis C drug given green light for EU market

Industry news / 9 August 2016 / MSD

Following successful phase 3 clinical trials, in which MSD’s new Hepatitis C drug, Zepatier, performed well, achieving high virologic cure rates across the study, the European Commission has licensed the drug for sale in the European market, specifically for the treatment of chronic hepatitis C virus (HCV) in adults with genotype 1 and 4 infection…

elbasvir

MSD announces positive results from elbasvir/grazoprevir HCV study

Industry news / 14 April 2016 / Victoria White, Digital Content Producer

Elbasvir/grazoprevir demonstrated superiority on efficacy and improvement on safety endpoints compared to sofosbuvir plus pegIFN/RBV…

GO-COLITIS

MSD presents data from Simponi GO-COLITIS trial

Industry news / 21 March 2016 / Victoria White

GO-COLITIS evaluated the efficacy of Simponi (golimumab) in inducing and maintaining clinical response in patients with moderate to severe ulcerative colitis…

Sanofi Pasteur and MSD

Sanofi Pasteur and MSD to end joint vaccines operations in Europe

Industry news / 8 March 2016 / Victoria White

Upon concluding their joint venture, Sanofi Pasteur and MSD plan to integrate their respective European vaccine businesses into their operations…

Golimumab

Golimumab shows higher treatment persistence rates in patients with IMRD

Industry news / 16 February 2016 / Victoria White

A study shows that patients initiating treatment with golimumab had significantly higher persistence rates than those initiating treatment with adalimumab or etanercept at 3 years.

dmards

NICE recommends 7 DMARDs for severe rheumatoid arthritis

Industry news / 26 January 2016 / Victoria White

NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs…

pd-l1

Pembrolizumab improves survival in PD-L1 expressing NSCLC

Industry news / 21 December 2015 / Victoria White

MSD has announced results from the Phase 2/3 KEYNOTE-010 study of Keytruda (pembrolizumab) in patients with previously treated non-small cell lung cancer (NSCLC)…

cytos

SMC accepts Keytruda as a treatment option for advanced melanoma

Industry news / 10 November 2015 / Victoria White

The SMC also announced positive recommendations for Roche’s Avastin (bevacizumab) and Daiichi Sankyo’s Lixiana (edoxaban)…

keytruda

Another NICE recommendation for melanoma drug Keytruda

Industry news / 9 October 2015 / Victoria White

This new recommendation for Keytruda is for treating advanced melanoma that has not been previously treated with ipilimumab…

pembrolizumab

NICE says ‘yes’ to pembrolizumab for advanced melanoma

Industry news / 7 October 2015 /

Pembrolizumab was the first drug to be approved through the Medicines and Healthcare Products Regulatory Agency’s Early Access to Medicine Scheme (EAMS)…

melanoma-pembrolizumab

NICE recommends melanoma drug pembrolizumab

Industry news / 7 September 2015 / Victoria White

NICE has recommended that pembrolizumab is made available on the NHS as a treatment for some patients with advanced melanoma which is either unresectable or metastatic…

sitagliptin

Cardiovascular safety trial of sitagliptin met primary endpoint in patients with type 2 diabetes

Industry news / 30 June 2015 / Victoria White

MSD recently announced the primary results of the TECOS trial, a placebo-controlled study of the cardiovascular safety of MSD’s DPP-4 inhibitor, sitagliptin…

 

Webinar: Different thermal analysis techniques to measure the glass transitionWATCH NOW
+ +